4894
Cuorips Inc.
クオリプス
- Industry
- Pharmaceutical
- Market
- Growth
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Consolidated
Notes
- Consolidation basisConsolidated / Since Mar 2024
Key metrics
Revenue(thousand JPY)
Mar 2023
38,278
Mar 2024
23,102
Mar 2025
175,205
Operating profit(thousand JPY)
Mar 2023
-450,435
Mar 2024
-588,487
Mar 2025
-590,262
Operating profit margin(%)
Mar 2023
-1,176.75
Mar 2024
-2,547.34
Mar 2025
-336.9
Profit before tax(thousand JPY)
Mar 2023
-449,878
Mar 2024
-629,953
Mar 2025
-642,014
Profit(thousand JPY)
Mar 2023
-452,077
Mar 2024
-632,183
Mar 2025
-644,342
Total assets(thousand JPY)
Mar 2023
3,587,417
Mar 2024
6,184,738
Mar 2025
5,741,609
Cash and cash equivalents(thousand JPY)
Mar 2023
2,941,896
Mar 2024
5,582,270
Mar 2025
4,793,824
Cash flows from operating activities(thousand JPY)
Mar 2023
-401,612
Mar 2024
-451,060
Mar 2025
-812,616
Cash flows from investing activities(thousand JPY)
Mar 2023
-8,968
Mar 2024
-34,998
Mar 2025
-119,992
Cash flows from financing activities(thousand JPY)
Mar 2023
10,694
Mar 2024
3,125,418
Mar 2025
145,113
Return on equity(-)
Mar 2023
-
Mar 2024
-
Mar 2025
-
Equity ratio(%)
Mar 2023
95.8
Mar 2024
96.6
Mar 2025
96.1
Earnings per share(JPY per share)
Mar 2023
-79.9
Mar 2024
-85.86
Mar 2025
-80.52
Net assets per share(JPY per share)
Mar 2023
607.17
Mar 2024
751.28
Mar 2025
681.88
Dividend per share(-)
Mar 2023
-
Mar 2024
-
Mar 2025
-
Payout ratio(-)
Mar 2023
-
Mar 2024
-
Mar 2025
-
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.